On Friday, Shares of Mosaic Co (NYSE:MOS), lost -3.33% to $31.24.
The Mosaic Company (MOS) has declared it will take part in the forthcoming Citi’s 2015 Basic Materials Conference to be held in New York City. Joc O’Rourke, Mosaic’s President and Chief Executive Officer, will present at the conference on Wednesday, December 2, 2015, at 9:30 a.m. Eastern Standard Time.
The Mosaic Company produces and markets concentrated phosphate and potash crop nutrients for the agricultural industry worldwide. It operates through two segments, Phosphates and Potash.
Shares of Immuno Cellular Therapeutics Ltd (NYSEMKT:IMUC), declined -17.15% to $0.430, during its last trading session.
Immuno Cellular Therapeutics, declared the presentation recently of recently updated overall survival (OS) results and immune response data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. The data are being presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, being held in San Antonio, TX. The data from the phase 2 trial continue to indicate a survival advantage in the ICT-107 treated group contrast to the control group. The data also show a noteworthy association between immune response and survival, especially in HLA-A2 positive (HLA-A2+) patients, which is the target patient population for the phase 3 registration trial.
- OS results were analyzed at three years after the last patient enrolled. For the 124-patient intent-to-treat population (ITT), median OS was 1.6 months or 10% better for ICT-107 patients than control. The difference in the Kaplan-Meier (KM) survival curves for this patient population was not statistically significant.
- Updated OS results for the pre-specified subgroup of HLA-A2+ patients continue to support selecting this patient population alone for a well powered phase 3 trial. For the MGMT methylated, HLA-A2+ PP population, median OS was 13.8 months or 58% better for ICT-107 treated patients than control. For the MGMT unmethylated, HLA-A2+ per-protocol (PP) population, median OS was 4.0 months or 34% better for ICT-107 treated patients than control. The differences in the KM survival curves for these two pre-specified phase 2 sub-populations were not powered for, and did not achieve, statistical significance.
- ELISPOT evaluation of antigen-specific immune response demonstrated a more frequent immune response in HLA-A2+ patients contrast with HLA-A1 patients, and this difference was statistically significant. This raised immune response in HLA-A2+ patients further supports the selection of HLA-A2+ patients exclusively for inclusion in the phase 3 trial.
- In HLA-A2+ patients, immune response was shown to be associated with survival. 60% of ICT-107 treated patients demonstrated a statistically noteworthy immune response contrast to only 36% of control patients. In a KM comparison of OS for immune responders as compared to non-responders, the responder curve showed a statistically noteworthy survival benefit with a log-rank p-value of 0.0084. For ICT-107 treated patients, the KM comparison of OS for responders as compared to non-responders showed a statistically noteworthy survival benefit with a log-rank p-value of 0.0147. The Company believes that the relationship between immune response and OS supports the phase 3 design improvement of adding more ICT-107 doses for patients in the first year of the protocol.
- Immune response did not differ statistically for MGMT methylated contrast to unmethylated patients. This result supports counting both MGMT types of patients in phase 3 testing.
- Of particular interest was the unpredictable finding that there was an raised immune response in some control patients post-treatment. One potential explanation is that the phase 2 control (activated dendritic cells without peptide loading) was immunologically active. The phase 3 design employs a different control comprising the patients’ own monocytes, which are less immunologically active than dendritic cells. This control could assist clarify a potential survival difference between ICT-107 and control treated patients.
Immuno Cellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate comprises ICT-107, a dendritic cell (DC) vaccine that accomplished Phase II testing trials for the treatment of glioblastoma multiforme (GBM).
Finally, Shares of Humana Inc (NYSE:HUM), ended its last trade with 2.05% gain, and closed at $167.61.
Humana Inc., has been identified as a U.S. leader for the quality of climate change-related information that it has revealed to investors and the global marketplace through CDP, the international not-for-profit that drives sustainable economies. This distinction awards Humana a position on the S&P Climate Disclosure Leadership Index (CDLI), released recently in the S&P edition of CDP’s annual global climate change report.
Humana earned its position on the index by disclosing high-quality carbon emissions, energy data and a strategy to address climate change-related risks through CDP’s climate change program. The stated data has been independently assessed against CDP’s scoring methodology and marked out of 100. Those organizations graded within the top 10 percent constitute the CDLI. Humana scored 100 on the disclosure index placing it at the top in the healthcare sector.
“Environmental sustainability is a part of the culture at Humana, and we’re honored to be recognized for our energy efficiencies and disclosure efforts,” said Tim Huval, Senior Vice President & Chief Human Resources Officer at Humana. “We’re intentional about reducing our carbon footprint and sharing the impactful results with the business community and more importantly, the communities we serve.”
Humana Inc., together with its auxiliaries, operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. The Retail segment provides Medicare and commercial fully-insured medical and specialty health insurance benefits, counting dental, vision, and other supplemental health and financial protection products directly to individuals.